Display options
Cite
Donlon NE, Davern M, Sheppard A, et al. The Prognostic Value of the Lymph Node in Oesophageal Adenocarcinoma; Incorporating Clinicopathological and Immunological Profiling. Cancers (Basel). 2021;13(16)doi: 10.3390/cancers13164005.
Donlon, N. E., Davern, M., Sheppard, A., Power, R., O'Connell, F., Heeran, A. B., King, R., Hayes, C., Bhardwaj, A., Phelan, J. J., Dunne, M. R., Ravi, N., Donohoe, C. L., O'Sullivan, J., Reynolds, J. V., & Lysaght, J. (2021). The Prognostic Value of the Lymph Node in Oesophageal Adenocarcinoma; Incorporating Clinicopathological and Immunological Profiling. Cancers, 13(16), . https://doi.org/10.3390/cancers13164005
Donlon, Noel E, et al. "The Prognostic Value of the Lymph Node in Oesophageal Adenocarcinoma; Incorporating Clinicopathological and Immunological Profiling." Cancers vol. 13,16 (2021). doi: https://doi.org/10.3390/cancers13164005
Donlon NE, Davern M, Sheppard A, Power R, O'Connell F, Heeran AB, King R, Hayes C, Bhardwaj A, Phelan JJ, Dunne MR, Ravi N, Donohoe CL, O'Sullivan J, Reynolds JV, Lysaght J. The Prognostic Value of the Lymph Node in Oesophageal Adenocarcinoma; Incorporating Clinicopathological and Immunological Profiling. Cancers (Basel). 2021 Aug 09;13(16). doi: 10.3390/cancers13164005. PMID: 34439160; PMCID: PMC8391676.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Aug 09;13(16). doi: 10.3390/cancers13164005.

The Prognostic Value of the Lymph Node in Oesophageal Adenocarcinoma; Incorporating Clinicopathological and Immunological Profiling.

Cancers

Noel E Donlon, Maria Davern, Andrew Sheppard, Robert Power, Fiona O'Connell, Aisling B Heeran, Ross King, Conall Hayes, Anshul Bhardwaj, James J Phelan, Margaret R Dunne, Narayanasamy Ravi, Claire L Donohoe, Jacintha O'Sullivan, John V Reynolds, Joanne Lysaght

Affiliations

  1. Department of Surgery, Trinity Translational Medicine Institute, Trinity College Dublin, St James's Hospital, D08 W9RT Dublin, Ireland.
  2. Trinity St James's Cancer Institute, St James's Hospital, D08 W9RT Dublin, Ireland.

PMID: 34439160 PMCID: PMC8391676 DOI: 10.3390/cancers13164005

Abstract

Response rates to the current gold standards of care for treating oesophageal adenocarcinoma (OAC) remain modest with 15-25% of patients achieving meaningful pathological responses, highlighting the need for novel therapeutic strategies. This study consists of immune, angiogenic, and inflammatory profiling of the tumour microenvironment (TME) and lymph node microenvironment (LNME) in OAC. The prognostic value of nodal involvement and clinicopathological features was compared using a retrospective cohort of OAC patients (

Keywords: immune checkpoints; immunophenotyping; metastatic niche; oesophageal adenocarcinoma; prognostic; tumour-draining lymph node

References

  1. Cancer Immunol Res. 2017 Nov;5(11):969-977 - PubMed
  2. J Immunother Cancer. 2019 May 22;7(1):133 - PubMed
  3. Science. 2001 Jul 13;293(5528):293-7 - PubMed
  4. Ann Surg. 2013 Nov;258(5):784-92; discussion 792 - PubMed
  5. Ann Surg. 2014 Nov;260(5):779-84; discussion 784-5 - PubMed
  6. Br J Surg. 2017 Dec;104(13):1816-1828 - PubMed
  7. Blood. 2011 Sep 1;118(9):2502-10 - PubMed
  8. Cancer Immunol Immunother. 2003 Oct;52(10):617-24 - PubMed
  9. J Clin Oncol. 2016 Aug 10;34(23):2721-7 - PubMed
  10. Front Immunol. 2014 Jun 17;5:276 - PubMed
  11. Clin Cancer Res. 2005 Nov 1;11(21):7683-91 - PubMed
  12. Nat Rev Immunol. 2017 Sep;17(9):559-572 - PubMed
  13. Ann Thorac Surg. 2006 Aug;82(2):480-4; discussion 484-5 - PubMed
  14. Cell Immunol. 2012;272(2):166-74 - PubMed
  15. Cancer Lett. 2021 Apr 1;502:84-96 - PubMed
  16. Nat Commun. 2018 May 29;9(1):2113 - PubMed
  17. Cancer Immunol Immunother. 2019 Oct;68(10):1681-1688 - PubMed
  18. N Engl J Med. 1998 Dec 31;339(27):1979-84 - PubMed
  19. J Clin Oncol. 2018 Jan 1;36(1):61-67 - PubMed
  20. Ann Surg Oncol. 2016 Dec;23(Suppl 5):998-1004 - PubMed
  21. Anticancer Res. 2018 Feb;38(2):893-900 - PubMed
  22. Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E761-E770 - PubMed
  23. Ann Surg Oncol. 2008 Oct;15(10):2894-902 - PubMed
  24. Science. 2018 Mar 23;359(6382):1403-1407 - PubMed
  25. Clin Cancer Res. 2018 Oct 15;24(20):5058-5071 - PubMed
  26. World J Gastroenterol. 2013 Dec 28;19(48):9282-93 - PubMed
  27. Ann Surg. 2008 Feb;247(2):365-71 - PubMed
  28. PLoS One. 2013;8(1):e53798 - PubMed
  29. Ann Surg. 2020 Nov;272(5):814-819 - PubMed
  30. Immunity. 2013 Jul 25;39(1):1-10 - PubMed
  31. Ann Surg. 1907 Jul;46(1):1-19 - PubMed
  32. Nat Rev Gastroenterol Hepatol. 2020 May;17(5):298-313 - PubMed
  33. Front Oncol. 2020 Jun 04;10:891 - PubMed
  34. Science. 2018 Mar 23;359(6382):1408-1411 - PubMed
  35. Ann Surg. 2017 Jan;265(1):122-129 - PubMed
  36. Cancer Immunol Immunother. 2018 Jan;67(1):47-60 - PubMed
  37. Ann Surg. 2008 Oct;248(4):549-56 - PubMed
  38. Cancer Immunol Res. 2015 Jan;3(1):48-58 - PubMed
  39. Int J Mol Sci. 2021 Jan 22;22(3): - PubMed
  40. Cancer. 1994 Jun 1;73(11):2680-6 - PubMed
  41. Ann Surg. 2017 Feb;265(2):356-362 - PubMed
  42. JCI Insight. 2018 Dec 6;3(23): - PubMed
  43. Br J Surg. 2020 Jul;107(8):1042-1052 - PubMed
  44. Cancers (Basel). 2020 Nov 13;12(11): - PubMed
  45. Science. 1996 Mar 22;271(5256):1734-6 - PubMed

Publication Types